Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Saint Louis, Missouri 63110


This clinical trial studies the long term safety and efficacy of asfotase alfa in children with HPP who completed Study ENB-006-09 (NCT00952484).

Study summary:

Asfotase alfa was formerly referred to as ENB-0040 Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs, including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure. There are limited data available on the natural course of this disease over time, particularly in patients with the juvenile-onset form.


Inclusion Criteria: - Compliant and satisfactory completion of Enobia-sponsored clinical trial ENB-006-09 - Written informed consent by parent or other legal guardian prior to any study procedures being performed - Parent or other legal guardian willing to comply with study requirements Exclusion Criteria: - Clinically significant disease that precludes study participation, in the Investigator's opinion - Treatment with an investigational drug other than asfotase alfa - Enrollment in any study (other than ENB-006-09) involving an investigational drug, device, or treatment for HPP - Prior treatment with bisphosphonates



Primary Contact:


Backup Contact:


Location Contact:

Saint Louis, Missouri 63110
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.